- Ocugen Inc. is a biotechnology company focused on gene and cell therapies and inhalable vaccine development.
- Their OCU400 program, targeting inherited eye diseases, is progressing to phase 3 clinical trials in 2024.
- The company’s participation in a $5 billion NIAID-funded trial for an inhaled COVID-19 vaccine enhances its financial and strategic position.
- Funding concerns loom with a cash runway of under a year, necessitating further capital infusion to continue R&D.
- Despite risks, Ocugen’s promising pipeline, particularly OCU400, positions it as a speculative “buy” with substantial upside.
ktsimage/iStock via Getty Images
Ocugen Inc. (NASDAQ:OCGN) is a clinical-stage biotechnology company based in Malvern, Pennsylvania. It is focused on gene and cell therapies and inhalable vaccine development. The OCU400 program, with indications for RP, adRP, and LCA, is progressing to phase 3 clinical trials in 1H 2024. NeoCart, a cell therapy for knee repair, has also advanced to phase 3 trials. Finally, OCGN’s participation in the $5 billion NIAID-funded trial for OCU500 inhaled COVID-19 vaccine enhances the company’s financial and strategic position. In my valuation analysis, I conclude that OCGN is a reasonably good speculative “buy” despite its inherent risks, as it holds significant upside potential if it delivers on its revenue projections.
READ FULL ARTICLE HERE!
